Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Felix von Podewils is active.

Publication


Featured researches published by Felix von Podewils.


Epilepsia | 2016

Costs and cost-driving factors for acute treatment of adults with status epilepticus: A multicenter cohort study from Germany

Lena-Marie Kortland; Anne Alfter; Oliver Bähr; Barbara Carl; Richard Dodel; Thomas M. Freiman; Kristina Hubert; Kolja Jahnke; Susanne Knake; Felix von Podewils; Jens-Peter Reese; Uwe Runge; Christian Senft; Helmuth Steinmetz; Felix Rosenow; Adam Strzelczyk

To provide first data on inpatient costs and cost‐driving factors due to nonrefractory status epilepticus (NSE), refractory status epilepticus (RSE), and super‐refractory status epilepticus (SRSE).


Epilepsia | 2017

Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany

Isabel Steinig; Felix von Podewils; Gabriel Möddel; Sebastian Bauer; Karl Martin Klein; Esther Paule; Philipp S. Reif; Laurent M. Willems; Johann Philipp Zöllner; Rhina Kunz; Uwe Runge; Gerhard Kurlemann; Susanne Schubert-Bast; Felix Rosenow; Adam Strzelczyk

To evaluate factors predicting efficacy, retention, and tolerability of add‐on brivaracetam (BRV) in clinical practice.


Epilepsy & Behavior | 2017

Treatment of refractory and super-refractory status epilepticus with brivaracetam: A cohort study from two German university hospitals

Adam Strzelczyk; Isabel Steinig; Laurent M. Willems; Philipp S. Reif; Christian Senft; Martin Voss; Bernadette Gaida; Felix von Podewils; Felix Rosenow

PURPOSE We aimed to ascertain the possible use of brivaracetam (BRV) as an option for treatment of status epilepticus (SE). METHODS A review of medical records was carried out to detect BRV administration in SE patients treated in Frankfurt and Greifswald during the period February 2016 to January 2017. The primary outcome question concerned SE resolution after BRV initiation. RESULTS During that period, BRV was started with eleven adult patients with SE. Five of these were female, and the median age was 64 (interquartile range [IQR] 21years). The median SE duration before BRV initiation was 5days (IQR 9days); the median number of previous anticonvulsants used was 4 (IQR 5). Initial BRV doses ranged between 50mg and 400mg (median 100mg), titrated to a daily dose of 100 to 400mg (median 200mg). There was a cessation of SE in the first 24h of BRV in three patients (27%). While taking BRV, no serious side effects were seen. CONCLUSION Based on these cases and previous data from animal experiments, BRV may prove useful in SE treatment, and trials would be warranted to examine BRVs efficacy in treating SE and how this efficacy might be influenced by co-administration with levetiracetam.


Frontiers in Neurology | 2017

Socioeconomic Outcome and Quality of Life in Adults after Status Epilepticus: A Multicenter, Longitudinal, Matched Case–Control Analysis from Germany

Lena-Marie Kortland; Susanne Knake; Felix von Podewils; Felix Rosenow; Adam Strzelczyk

Background There is a lack of data concerning socioeconomic outcome and quality of life (QoL) in patients after status epilepticus (SE) in Germany. Patients and methods Adult patients treated between 2011 and 2015 due to SE at the university hospitals in Frankfurt, Greifswald, and Marburg were asked to fill out a questionnaire regarding long-term outcome of at least 3 months after discharge. The SE cohort consisted of 25.9% patients with an acute symptomatic, 42% with a remote symptomatic and previous epilepsy, 22.2% with a new-onset remote symptomatic, and 9.9% with other or unknown etiology. A matched case–control analysis was applied for comparison with patients with drug refractory epilepsy and seizure remission, both not previously affected by SE. Results A total of 81 patients (mean age: 58.7 ± 18.0 years; 58% female) participated. A non-refractory course was present in 59.3%, while 27.2% had a refractory SE (RSE) and 13.6% had a superrefractory SE (SRSE). Before admission, a favorable modified Rankin Scale (mRS) of 0–3 was found in 82.7% (67/81), deteriorating to 38.3% (31/81) (p = 0.003) at discharge. The majority returned home [51.9% (42/81)], 32.1% entered a rehabilitation facility, while 12.3% were transferred to a nursing home and 3.7% to another hospital. The overall mRS at follow-up did not change; 61.8% (45/74) reached an mRS of 0–3. In RSE and SRSE, the proportion with a favorable mRS increased from 45.5% at discharge to 70% at follow-up, while QoL was comparable to a non-refractory SE course. Matched epilepsy controls in seizure remission were treated with a lower mean number of anticonvulsants (1.3 ± 0.7) compared to controls with drug refractory epilepsy (1.9 ± 0.8; p < 0.001) or SE (1.9 ± 1.1; p < 0.001). A major depression was found in 32.8% of patients with SE and in 36.8% of drug refractory epilepsy, but only in 20.3% of patients in seizure remission. QoL was reduced in all categories (QOLIE-31) in SE patients in comparison with patients in seizure remission, but was comparable to patients with drug refractory epilepsy. Discussion Patients after SE show substantial impairments in their QoL and daily life activities. However, in the long term, patients with RSE and SRSE had a relatively favorable outcome comparable to that of patients with a non-refractory SE course. This underlines the need for efficient therapeutic options in SE.


Epilepsia | 2017

Prevalence and outcome of late‐onset seizures due to autoimmune etiology: A prospective observational population‐based cohort study

Felix von Podewils; Marie Suesse; Julia Geithner; Bernadette Gaida; Zhong I. Wang; Julia Lange; Alexander Dressel; Matthias Grothe; Christof Kessler; Soenke Langner; Uwe Runge; Christian G. Bien

The increasing incidence of new‐onset seizures with age is well known. Often, the etiology cannot be clarified. In the present study, patients with unprovoked late‐onset seizures and without known neoplasm, who might have had paraneoplastic encephalitis, were investigated for a potentially underlying autoimmunity.


Epilepsy & Behavior | 2015

Predictive value of EFHC1 variants for the long-term seizure outcome in juvenile myoclonic epilepsy

Felix von Podewils; Victoria Kowoll; Winnie Schroeder; Julia Geithner; Zhong I. Wang; Bernadette Gaida; Paula Bombach; Christof Kessler; Ute Felbor; Uwe Runge

OBJECTIVE This study aimed to determine the contribution of EFHC1 variants to the phenotypic variability of juvenile myoclonic epilepsy (JME) and to evaluate their diagnostic value regarding previously identified clinical long-term seizure outcome predictors in a consecutive cohort of patients with JME. METHODS Thirty-eight probands and three family members affected with JME were studied at a tertiary epilepsy center with a review of their medical records and a subsequent face-to-face interview. All coding EFHC1 exons and adjacent exon/intron boundaries were directly sequenced. RESULTS The previously reported EFHC1 mutation F229L was found in two cases who presented with early generalized tonic-clonic seizure (GTCS) onset and appeared to be associated with milder subtypes of JME. Variant R294H was identified in two further probands who had a subtype of JME developing from childhood absence epilepsy. However, segregation of the phenotype with this variant could not be confirmed in one family. CONCLUSIONS Our findings corroborate the heterogeneity of JME as an electroclinical epilepsy syndrome and provide evidence that genetic factors may influence and help predict the long-term seizure outcome in patients with JME.


Epilepsy Research | 2014

Natural course and predictors of spontaneous seizure remission in idiopathic generalized epilepsy: 7–27 years of follow-up

Felix von Podewils; Sabine Lapp; Z. Irene Wang; Ute Hartmann; Rosemarie Herzer; Christof Kessler; Uwe Runge

The spontaneous course of idiopathic generalized epilepsy (IGE) is still controversial. The aim of this study was both to investigate the long-term spontaneous course and to identify factors that are predictive for epilepsy remission in a small cohort of 15 IGE patients (9 women) who refused antiepileptic drug (AED) treatment and therefore never have been treated with AED. All of them were reevaluated with a review of their medical records and direct face-to-face interview; the mean duration of follow-up was 15.3 years. Five (33.3%) of them had absence epilepsy (absence seizures, ABS), 5 had IGE with generalized tonic-clonic seizures (GTCS), and another 5 had both seizure types (IGE with ABS/GTCS). Rate of epilepsy remission was 53.3% with a mean time of seizure freedom of 13.1 years; rate of remission was highest among absence epilepsy patients (80%), followed by IGE with GTCS (60%) and IGE with ABS/GTCS (20%). The frequency of spontaneous generalized interictal epileptiform discharges in electroencephalography is not associated with the long-term seizure outcome (p=0.201) and per se does not require AED treatment. Furthermore, the occurrence of photoparoxysmal responses (p=0.020) as well as the occurrence of more than 3 GTCS during the course (p=0.029) were identified as significant predictors for a poor long-term seizure outcome which makes AED treatment indispensable in these patients. This study underlines the heterogenity of the group of IGE. AED treatment has no impact on the spontaneous course of IGE with ABS and/or GTCS. Several predictors for the long-term seizure outcome in patients with IGE were identified in this study.


Epilepsia | 2018

Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus

Adam Strzelczyk; Lara Kay; Sebastian Bauer; Ilka Immisch; Karl Martin Klein; Susanne Knake; Alexander B. Kowski; Rhina Kunz; Gerhard Kurlemann; Lisa Langenbruch; Gabriel Möddel; Karen Müller-Schlüter; Philipp S. Reif; Susanne Schubert-Bast; Bernhard J. Steinhoff; Isabel Steinig; Laurent M. Willems; Felix von Podewils; Felix Rosenow

The objective of this study was to evaluate effectiveness, retention, and tolerability of brivaracetam (BRV) in genetic generalized epilepsies (GGE) in clinical practice.


Frontiers in Neurology | 2018

Efficacy, Retention, and Tolerability of Brivaracetam in Patients With Epileptic Encephalopathies: A Multicenter Cohort Study From Germany

Laurent M. Willems; Astrid Bertsche; Frank Bösebeck; Frauke Hornemann; Ilka Immisch; Karl Martin Klein; Susanne Knake; Rhina Kunz; Gerhard Kurlemann; Lisa Langenbruch; Gabriel Möddel; Karen Müller-Schlüter; Felix von Podewils; Philipp S. Reif; Bernhard J. Steinhoff; Isabel Steinig; Felix Rosenow; Susanne Schubert-Bast; Adam Strzelczyk

Objective: To evaluate the efficacy and tolerability of brivaracetam (BRV) in a severely drug refractory cohort of patients with epileptic encephalopathies (EE). Method: A multicenter, retrospective cohort study recruiting all patients treated with EE who began treatment with BRV in an enrolling epilepsy center between 2016 and 2017. Results: Forty-four patients (27 male [61%], mean age 29 years, range 6 to 62) were treated with BRV. The retention rate was 65% at 3 months, 52% at 6 months and 41% at 12 months. A mean retention time of 5 months resulted in a cumulative exposure to BRV of 310 months. Three patients were seizure free during the baseline. At 3 months, 20 (45%, 20/44 as per intention-to-treat analysis considering all patients that started BRV including three who were seizure free during baseline) were either seizure free (n = 4; 9%, three of them already seizure-free at baseline) or reported at least 25% (n = 4; 9%) or 50% (n = 12; 27%) reduction in seizures. An increase in seizure frequency was reported in two (5%) patients, while there was no change in the seizure frequency of the other patients. A 50% long-term responder rate was apparent in 19 patients (43%), with two (5%) free from seizures for more than six months and in nine patients (20%, with one [2 %] free from seizures) for more than 12 months. Treatment-emergent adverse events were predominantly of psychobehavioural nature and were observed in 16%. Significance: In this retrospective analysis the rate of patients with a 50% seizure reduction under BRV proofed to be similar to those seen in regulatory trials for focal epilepsies. BRV appears to be safe and relatively well tolerated in EE and might be considered in patients with psychobehavioral adverse events while on levetiracetam.


Frontiers in Neurology | 2018

Juvenile Myoclonic Epilepsy Shows Potential Structural White Matter Abnormalities: A TBSS Study

Martin Domin; Sabine Bartels; Julia Geithner; Zhong I. Wang; Uwe Runge; Matthias Grothe; Soenke Langner; Felix von Podewils

Background: Several studies on patients with juvenile myoclonic epilepsy (JME) showed widespread white matter (WM) abnormalities in the brain. The aim of this study was to investigate potential structural abnormalities in JME patients (1) compared to healthy controls, (2) among JME subgroups with or without photoparoxysmal responses (PPR), and (3) in correlation with clinical variables. Methods: A selection of 31 patients with JME (12 PPR positive) and 27 age and gender matched healthy controls (HC) were studied at a tertiary epilepsy center. Fractional anisotropy (FA) was calculated and intergroup differences analyzed using Tract Based Spatial Statistics (TBSS). Results: Compared to HC the JME group showed reduced FA widespread and bilateral in the longitudinal fasciculus, inferior fronto-occipital fasciculus, corticospinal tract, anterior and posterior thalamic radiation, corona radiata, corpus callosum, cingulate gyrus and external capsule (p < 0.01). Subgroup analysis revealed no significant differences of WM alterations between PPR positive and negative patients and with clinical and epilepsy-related factors. Conclusions: Widespread microstructural abnormalities among patients with JME have been identified.Prior findings of frontal and thalamofrontal microstructural abnormalities have been confirmed. Additionally, microstructural abnormalities were found in widespread extra-frontal regions that may help to validate pathophysiological concepts of JME.

Collaboration


Dive into the Felix von Podewils's collaboration.

Top Co-Authors

Avatar

Felix Rosenow

Goethe University Frankfurt

View shared research outputs
Top Co-Authors

Avatar

Uwe Runge

University of Greifswald

View shared research outputs
Top Co-Authors

Avatar

Adam Strzelczyk

Goethe University Frankfurt

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Isabel Steinig

Goethe University Frankfurt

View shared research outputs
Top Co-Authors

Avatar

Laurent M. Willems

Goethe University Frankfurt

View shared research outputs
Top Co-Authors

Avatar

Philipp S. Reif

Goethe University Frankfurt

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge